{"DataElement":{"publicId":"2787521","version":"1","preferredName":"Daclizumab Administered Specify Text","preferredDefinition":"The free-text field to describe the daclizumab that was administered.","longName":"DAC_ADMIN_SPEC","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2787464","version":"1","preferredName":"Daclizumab Administered","preferredDefinition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway._The act of having given something (e.g., a medication or test).","longName":"DAC_ADMIN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2861841","version":"1","preferredName":"Daclizumab","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","longName":"C1569","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"68154BB0-E816-8CDE-E040-BB89AD435355","latestVersionIndicator":"Yes","beginDate":"2009-04-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57AB6A8C-6F4F-5822-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-24","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2799057","version":"1","preferredName":"Specify Text","preferredDefinition":"Be specific about something; define clearly._Text; the words of something written.","longName":"SPC_TXT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2799056","version":"1","preferredName":"Specify Text","preferredDefinition":"Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D89B-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"ONEDATA","dateModified":"2008-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D8AC-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"MALUMK","dateModified":"2021-01-19","changeDescription":"03/17/10-Added CSI for F2000-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"},{"publicId":"2964923","version":"1","longName":"2300r1: Greater Than 2 Years Post-HSCT Data","context":"NHLBI"}]},{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842918","version":"1","longName":"Administration","context":"NHLBI"}]}],"AlternateNames":[{"name":"agvhd_trt_mab_cd25_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"cgvhd_trt_mab_cd25_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"agvhd_prevent_cd25_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"CCR","type":"USED_BY","context":"CCR"},{"name":"HPST_AGHD_daclizumab_specify","type":"NMDP_FN","context":"NHLBI"},{"name":"HPST_CGHD_daclizumab_specify","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the anti CD 25 admini","type":"Preferred Question Text","description":"Specify the anti CD 25 administered:","url":null,"context":"NHLBI"},{"name":"Specify:","type":"Alternate Question Text","description":"Specify:","url":null,"context":"NHLBI"},{"name":"Specify the anti CD 25 (Zenapax, Daclizumab, AntiTAC) used after the start of the preparative regimen to prevent acute GVHD or graft rejection:","type":"Alternate Question Text","description":"Specify the anti CD 25 (Zenapax, Daclizumab, AntiTAC) used after the start of the preparative regimen to prevent acute GVHD or graft rejection:","url":null,"context":"NHLBI"},{"name":"Specify anti CD25","type":"Alternate Question Text","description":"Specify anti CD25","url":null,"context":"NHLBI"},{"name":"Specify anti CD25:","type":"Application Standard Question Text","description":"Specify anti CD25:","url":null,"context":"NHLBI"},{"name":"Specify anti CD25:","type":"Alternate Question Text","description":"Specify anti CD25:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57B916A0-2A0D-4EC2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-25","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-25","modifiedBy":"MALUMK","dateModified":"2021-10-04","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 10/7/14. 2/25/16mn-added asqt and aqt. Specify anti CD25:. ALT name added for 2100r7. 10/04/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}